Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

[1]  S. Adami,et al.  Long‐term effects of a treatment course with oral alendronate of postmenopausal osteoporosis , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  H. Genant,et al.  Monitoring bone resorption in early postmenopausal women by an immunoassay for cross‐linked collagen peptides in urine , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  H. Genant,et al.  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. , 1993, The American journal of medicine.

[4]  E. Opas,et al.  The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. , 1993, The Journal of clinical investigation.

[5]  H. Genant,et al.  The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. , 1993, The Journal of clinical endocrinology and metabolism.

[6]  T. Martin,et al.  Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. , 1993, The Journal of clinical investigation.

[7]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[8]  Joseph F. Heyse,et al.  An Empirical and Simulated Comparison of Some Tests for Detecting Progressiveness of Response with Increasing Doses of a Compound , 1992 .

[9]  H. Fleisch.  Bisphosphonates , 2012, Drugs.

[10]  R. Epstein,et al.  Pre-existing fractures and bone mass predict vertebral fracture incidence in women. , 1991, Annals of internal medicine.

[11]  C. Christiansen,et al.  Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. , 1991, The Journal of clinical endocrinology and metabolism.

[12]  W. C. Thomas,et al.  The Effect of Hypoparathyroidism on the Aging Skeleton , 1990, Journal of the American Geriatrics Society.

[13]  W. Mysiw,et al.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[14]  B. Riis,et al.  Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. , 1990, The American journal of medicine.

[15]  J. Parker,et al.  Maternal Weight Gain in Women With Good Pregnancy Outcome , 1990, Obstetrics and gynecology.

[16]  H. Genant,et al.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[17]  Lloyd S. Nelson,et al.  Evaluating overlapping confidence intervals , 1989 .

[18]  R. Valkema,et al.  Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. , 1989, Bone and mineral.

[19]  R. Weinstein,et al.  Diminished rates of bone formation in normal black adults. , 1988, The New England journal of medicine.

[20]  P. Ross,et al.  Detection of prefracture spinal osteoporosis using bone mineral absorptiometry , 1988, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  S. H. Kan,et al.  Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. , 1988, Journal of clinical epidemiology.

[22]  G Block,et al.  Evaluation of two food frequency methods of measuring dietary calcium intake. , 1987, American journal of epidemiology.

[23]  H. Genant,et al.  Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. , 1987, Annals of internal medicine.

[24]  M. Gail,et al.  Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.

[25]  J W Tukey,et al.  Testing the statistical certainty of a response to increasing doses of a drug. , 1985, Biometrics.

[26]  W. Nelp,et al.  Long-term calcitonin therapy in postmenopausal osteoporosis. , 1984, Metabolism: clinical and experimental.

[27]  R. Altman,et al.  Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. , 1977, Annals of internal medicine.

[28]  R. Williams.  Letter: Polymyalgia rheumatica and liver disease. , 1974, Lancet.

[29]  M. Gyepes,et al.  The Low Incidence of Fracture of the Hip in the Negro , 1962 .